This research report provides a comprehensive analysis of the Drugs for Oncology market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Drugs for Oncology market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Drugs for Oncology, challenges faced by the industry, and potential opportunities for market players.
The global Drugs for Oncology market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Drugs for Oncology market presents opportunities for various stakeholders, including Blood Cancer, Breast Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Drugs for Oncology market. Additionally, the growing consumer demand present avenues for market expansion.
The global Drugs for Oncology market was valued at US$ 186220 million in 2023 and is projected to reach US$ 330340 million by 2030, at a CAGR of 8.4% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Drugs for Oncology market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Drugs for Oncology market.
Market Overview: The report provides a comprehensive overview of the Drugs for Oncology market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Chemotherapy, Targeted Therapy), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Drugs for Oncology market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Drugs for Oncology market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Drugs for Oncology market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Drugs for Oncology market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Drugs for Oncology market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Drugs for Oncology market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Drugs for Oncology, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Drugs for Oncology market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Drugs for Oncology market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Market segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
Global Drugs for Oncology Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Oncology, market overview.
Chapter 2: Global Drugs for Oncology market size in revenue.
Chapter 3: Detailed analysis of Drugs for Oncology company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Oncology in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Oncology Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Oncology Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Oncology Overall Market Size
2.1 Global Drugs for Oncology Market Size: 2023 VS 2030
2.2 Global Drugs for Oncology Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Oncology Players in Global Market
3.2 Top Global Drugs for Oncology Companies Ranked by Revenue
3.3 Global Drugs for Oncology Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Oncology Companies in Global Market, by Revenue in 2023
3.5 Global Companies Drugs for Oncology Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Oncology Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Oncology Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Oncology Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Oncology Market Size Markets, 2023 & 2030
4.1.2 Chemotherapy
4.1.3 Targeted Therapy
4.1.4 Immunotherapy (Biologic Therapy)
4.1.5 Hormonal Therapy
4.1.6 Others
4.2 By Type - Global Drugs for Oncology Revenue & Forecasts
4.2.1 By Type - Global Drugs for Oncology Revenue, 2019-2024
4.2.2 By Type - Global Drugs for Oncology Revenue, 2025-2030
4.2.3 By Type - Global Drugs for Oncology Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Oncology Market Size, 2023 & 2030
5.1.2 Blood Cancer
5.1.3 Breast Cancer
5.1.4 Gastrointestinal Cancer
5.1.5 Prostate Cancer
5.1.6 Respiratory/Lung Cancer
5.1.7 Others
5.2 By Application - Global Drugs for Oncology Revenue & Forecasts
5.2.1 By Application - Global Drugs for Oncology Revenue, 2019-2024
5.2.2 By Application - Global Drugs for Oncology Revenue, 2025-2030
5.2.3 By Application - Global Drugs for Oncology Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Drugs for Oncology Market Size, 2023 & 2030
6.2 By Region - Global Drugs for Oncology Revenue & Forecasts
6.2.1 By Region - Global Drugs for Oncology Revenue, 2019-2024
6.2.2 By Region - Global Drugs for Oncology Revenue, 2025-2030
6.2.3 By Region - Global Drugs for Oncology Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Drugs for Oncology Revenue, 2019-2030
6.3.2 US Drugs for Oncology Market Size, 2019-2030
6.3.3 Canada Drugs for Oncology Market Size, 2019-2030
6.3.4 Mexico Drugs for Oncology Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Drugs for Oncology Revenue, 2019-2030
6.4.2 Germany Drugs for Oncology Market Size, 2019-2030
6.4.3 France Drugs for Oncology Market Size, 2019-2030
6.4.4 U.K. Drugs for Oncology Market Size, 2019-2030
6.4.5 Italy Drugs for Oncology Market Size, 2019-2030
6.4.6 Russia Drugs for Oncology Market Size, 2019-2030
6.4.7 Nordic Countries Drugs for Oncology Market Size, 2019-2030
6.4.8 Benelux Drugs for Oncology Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Drugs for Oncology Revenue, 2019-2030
6.5.2 China Drugs for Oncology Market Size, 2019-2030
6.5.3 Japan Drugs for Oncology Market Size, 2019-2030
6.5.4 South Korea Drugs for Oncology Market Size, 2019-2030
6.5.5 Southeast Asia Drugs for Oncology Market Size, 2019-2030
6.5.6 India Drugs for Oncology Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Drugs for Oncology Revenue, 2019-2030
6.6.2 Brazil Drugs for Oncology Market Size, 2019-2030
6.6.3 Argentina Drugs for Oncology Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Oncology Revenue, 2019-2030
6.7.2 Turkey Drugs for Oncology Market Size, 2019-2030
6.7.3 Israel Drugs for Oncology Market Size, 2019-2030
6.7.4 Saudi Arabia Drugs for Oncology Market Size, 2019-2030
6.7.5 UAE Drugs for Oncology Market Size, 2019-2030
7 Drugs for Oncology Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Drugs for Oncology Major Product Offerings
7.1.4 Roche Drugs for Oncology Revenue in Global Market (2019-2024)
7.1.5 Roche Key News & Latest Developments
7.2 Celgene
7.2.1 Celgene Company Summary
7.2.2 Celgene Business Overview
7.2.3 Celgene Drugs for Oncology Major Product Offerings
7.2.4 Celgene Drugs for Oncology Revenue in Global Market (2019-2024)
7.2.5 Celgene Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Drugs for Oncology Major Product Offerings
7.3.4 Novartis Drugs for Oncology Revenue in Global Market (2019-2024)
7.3.5 Novartis Key News & Latest Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Company Summary
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Drugs for Oncology Major Product Offerings
7.4.4 Bristol-Myers Squibb Drugs for Oncology Revenue in Global Market (2019-2024)
7.4.5 Bristol-Myers Squibb Key News & Latest Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Company Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Drugs for Oncology Major Product Offerings
7.5.4 Johnson & Johnson Drugs for Oncology Revenue in Global Market (2019-2024)
7.5.5 Johnson & Johnson Key News & Latest Developments
7.6 Merck & Co.
7.6.1 Merck & Co. Company Summary
7.6.2 Merck & Co. Business Overview
7.6.3 Merck & Co. Drugs for Oncology Major Product Offerings
7.6.4 Merck & Co. Drugs for Oncology Revenue in Global Market (2019-2024)
7.6.5 Merck & Co. Key News & Latest Developments
7.7 AstraZeneca
7.7.1 AstraZeneca Company Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Drugs for Oncology Major Product Offerings
7.7.4 AstraZeneca Drugs for Oncology Revenue in Global Market (2019-2024)
7.7.5 AstraZeneca Key News & Latest Developments
7.8 Pfizer
7.8.1 Pfizer Company Summary
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Drugs for Oncology Major Product Offerings
7.8.4 Pfizer Drugs for Oncology Revenue in Global Market (2019-2024)
7.8.5 Pfizer Key News & Latest Developments
7.9 Amgen
7.9.1 Amgen Company Summary
7.9.2 Amgen Business Overview
7.9.3 Amgen Drugs for Oncology Major Product Offerings
7.9.4 Amgen Drugs for Oncology Revenue in Global Market (2019-2024)
7.9.5 Amgen Key News & Latest Developments
7.10 Eli Lilly
7.10.1 Eli Lilly Company Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly Drugs for Oncology Major Product Offerings
7.10.4 Eli Lilly Drugs for Oncology Revenue in Global Market (2019-2024)
7.10.5 Eli Lilly Key News & Latest Developments
7.11 AbbVie
7.11.1 AbbVie Company Summary
7.11.2 AbbVie Business Overview
7.11.3 AbbVie Drugs for Oncology Major Product Offerings
7.11.4 AbbVie Drugs for Oncology Revenue in Global Market (2019-2024)
7.11.5 AbbVie Key News & Latest Developments
7.12 Takeda
7.12.1 Takeda Company Summary
7.12.2 Takeda Business Overview
7.12.3 Takeda Drugs for Oncology Major Product Offerings
7.12.4 Takeda Drugs for Oncology Revenue in Global Market (2019-2024)
7.12.5 Takeda Key News & Latest Developments
7.13 Astellas
7.13.1 Astellas Company Summary
7.13.2 Astellas Business Overview
7.13.3 Astellas Drugs for Oncology Major Product Offerings
7.13.4 Astellas Drugs for Oncology Revenue in Global Market (2019-2024)
7.13.5 Astellas Key News & Latest Developments
7.14 Ipsen
7.14.1 Ipsen Company Summary
7.14.2 Ipsen Business Overview
7.14.3 Ipsen Drugs for Oncology Major Product Offerings
7.14.4 Ipsen Drugs for Oncology Revenue in Global Market (2019-2024)
7.14.5 Ipsen Key News & Latest Developments
7.15 Sanofi
7.15.1 Sanofi Company Summary
7.15.2 Sanofi Business Overview
7.15.3 Sanofi Drugs for Oncology Major Product Offerings
7.15.4 Sanofi Drugs for Oncology Revenue in Global Market (2019-2024)
7.15.5 Sanofi Key News & Latest Developments
7.16 Bayer
7.16.1 Bayer Company Summary
7.16.2 Bayer Business Overview
7.16.3 Bayer Drugs for Oncology Major Product Offerings
7.16.4 Bayer Drugs for Oncology Revenue in Global Market (2019-2024)
7.16.5 Bayer Key News & Latest Developments
7.17 Biogen Idec
7.17.1 Biogen Idec Company Summary
7.17.2 Biogen Idec Business Overview
7.17.3 Biogen Idec Drugs for Oncology Major Product Offerings
7.17.4 Biogen Idec Drugs for Oncology Revenue in Global Market (2019-2024)
7.17.5 Biogen Idec Key News & Latest Developments
7.18 Teva
7.18.1 Teva Company Summary
7.18.2 Teva Business Overview
7.18.3 Teva Drugs for Oncology Major Product Offerings
7.18.4 Teva Drugs for Oncology Revenue in Global Market (2019-2024)
7.18.5 Teva Key News & Latest Developments
7.19 Otsuka
7.19.1 Otsuka Company Summary
7.19.2 Otsuka Business Overview
7.19.3 Otsuka Drugs for Oncology Major Product Offerings
7.19.4 Otsuka Drugs for Oncology Revenue in Global Market (2019-2024)
7.19.5 Otsuka Key News & Latest Developments
7.20 Eisai
7.20.1 Eisai Company Summary
7.20.2 Eisai Business Overview
7.20.3 Eisai Drugs for Oncology Major Product Offerings
7.20.4 Eisai Drugs for Oncology Revenue in Global Market (2019-2024)
7.20.5 Eisai Key News & Latest Developments
7.21 Merck KGaA
7.21.1 Merck KGaA Company Summary
7.21.2 Merck KGaA Business Overview
7.21.3 Merck KGaA Drugs for Oncology Major Product Offerings
7.21.4 Merck KGaA Drugs for Oncology Revenue in Global Market (2019-2024)
7.21.5 Merck KGaA Key News & Latest Developments
7.22 Gilead Sciences
7.22.1 Gilead Sciences Company Summary
7.22.2 Gilead Sciences Business Overview
7.22.3 Gilead Sciences Drugs for Oncology Major Product Offerings
7.22.4 Gilead Sciences Drugs for Oncology Revenue in Global Market (2019-2024)
7.22.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Drugs for Oncology Market Opportunities & Trends in Global Market
Table 2. Drugs for Oncology Market Drivers in Global Market
Table 3. Drugs for Oncology Market Restraints in Global Market
Table 4. Key Players of Drugs for Oncology in Global Market
Table 5. Top Drugs for Oncology Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Drugs for Oncology Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Drugs for Oncology Revenue Share by Companies, 2019-2024
Table 8. Global Companies Drugs for Oncology Product Type
Table 9. List of Global Tier 1 Drugs for Oncology Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Oncology Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Drugs for Oncology Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Drugs for Oncology Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Drugs for Oncology Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Drugs for Oncology Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Drugs for Oncology Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Drugs for Oncology Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Drugs for Oncology Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Drugs for Oncology Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Drugs for Oncology Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Drugs for Oncology Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Drugs for Oncology Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Drugs for Oncology Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Drugs for Oncology Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Drugs for Oncology Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Drugs for Oncology Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Drugs for Oncology Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Drugs for Oncology Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Drugs for Oncology Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Drugs for Oncology Revenue, (US$, Mn), 2025-2030
Table 30. Roche Company Summary
Table 31. Roche Drugs for Oncology Product Offerings
Table 32. Roche Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 33. Roche Key News & Latest Developments
Table 34. Celgene Company Summary
Table 35. Celgene Drugs for Oncology Product Offerings
Table 36. Celgene Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 37. Celgene Key News & Latest Developments
Table 38. Novartis Company Summary
Table 39. Novartis Drugs for Oncology Product Offerings
Table 40. Novartis Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 41. Novartis Key News & Latest Developments
Table 42. Bristol-Myers Squibb Company Summary
Table 43. Bristol-Myers Squibb Drugs for Oncology Product Offerings
Table 44. Bristol-Myers Squibb Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 45. Bristol-Myers Squibb Key News & Latest Developments
Table 46. Johnson & Johnson Company Summary
Table 47. Johnson & Johnson Drugs for Oncology Product Offerings
Table 48. Johnson & Johnson Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 49. Johnson & Johnson Key News & Latest Developments
Table 50. Merck & Co. Company Summary
Table 51. Merck & Co. Drugs for Oncology Product Offerings
Table 52. Merck & Co. Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 53. Merck & Co. Key News & Latest Developments
Table 54. AstraZeneca Company Summary
Table 55. AstraZeneca Drugs for Oncology Product Offerings
Table 56. AstraZeneca Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 57. AstraZeneca Key News & Latest Developments
Table 58. Pfizer Company Summary
Table 59. Pfizer Drugs for Oncology Product Offerings
Table 60. Pfizer Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 61. Pfizer Key News & Latest Developments
Table 62. Amgen Company Summary
Table 63. Amgen Drugs for Oncology Product Offerings
Table 64. Amgen Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 65. Amgen Key News & Latest Developments
Table 66. Eli Lilly Company Summary
Table 67. Eli Lilly Drugs for Oncology Product Offerings
Table 68. Eli Lilly Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 69. Eli Lilly Key News & Latest Developments
Table 70. AbbVie Company Summary
Table 71. AbbVie Drugs for Oncology Product Offerings
Table 72. AbbVie Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 73. AbbVie Key News & Latest Developments
Table 74. Takeda Company Summary
Table 75. Takeda Drugs for Oncology Product Offerings
Table 76. Takeda Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 77. Takeda Key News & Latest Developments
Table 78. Astellas Company Summary
Table 79. Astellas Drugs for Oncology Product Offerings
Table 80. Astellas Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 81. Astellas Key News & Latest Developments
Table 82. Ipsen Company Summary
Table 83. Ipsen Drugs for Oncology Product Offerings
Table 84. Ipsen Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 85. Ipsen Key News & Latest Developments
Table 86. Sanofi Company Summary
Table 87. Sanofi Drugs for Oncology Product Offerings
Table 88. Sanofi Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 89. Sanofi Key News & Latest Developments
Table 90. Bayer Company Summary
Table 91. Bayer Drugs for Oncology Product Offerings
Table 92. Bayer Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 93. Bayer Key News & Latest Developments
Table 94. Biogen Idec Company Summary
Table 95. Biogen Idec Drugs for Oncology Product Offerings
Table 96. Biogen Idec Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 97. Biogen Idec Key News & Latest Developments
Table 98. Teva Company Summary
Table 99. Teva Drugs for Oncology Product Offerings
Table 100. Teva Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 101. Teva Key News & Latest Developments
Table 102. Otsuka Company Summary
Table 103. Otsuka Drugs for Oncology Product Offerings
Table 104. Otsuka Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 105. Otsuka Key News & Latest Developments
Table 106. Eisai Company Summary
Table 107. Eisai Drugs for Oncology Product Offerings
Table 108. Eisai Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 109. Eisai Key News & Latest Developments
Table 110. Merck KGaA Company Summary
Table 111. Merck KGaA Drugs for Oncology Product Offerings
Table 112. Merck KGaA Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 113. Merck KGaA Key News & Latest Developments
Table 114. Gilead Sciences Company Summary
Table 115. Gilead Sciences Drugs for Oncology Product Offerings
Table 116. Gilead Sciences Drugs for Oncology Revenue (US$, Mn) & (2019-2024)
Table 117. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Drugs for Oncology Segment by Type in 2023
Figure 2. Drugs for Oncology Segment by Application in 2023
Figure 3. Global Drugs for Oncology Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Drugs for Oncology Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Drugs for Oncology Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Oncology Revenue in 2023
Figure 8. By Type - Global Drugs for Oncology Revenue Market Share, 2019-2030
Figure 9. By Application - Global Drugs for Oncology Revenue Market Share, 2019-2030
Figure 10. By Type - Global Drugs for Oncology Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Drugs for Oncology Revenue Market Share, 2019-2030
Figure 12. By Application - Global Drugs for Oncology Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Drugs for Oncology Revenue Market Share, 2019-2030
Figure 14. By Region - Global Drugs for Oncology Revenue Market Share, 2019-2030
Figure 15. By Country - North America Drugs for Oncology Revenue Market Share, 2019-2030
Figure 16. US Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Drugs for Oncology Revenue Market Share, 2019-2030
Figure 20. Germany Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 21. France Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Drugs for Oncology Revenue Market Share, 2019-2030
Figure 28. China Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 32. India Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Drugs for Oncology Revenue Market Share, 2019-2030
Figure 34. Brazil Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Drugs for Oncology Revenue Market Share, 2019-2030
Figure 37. Turkey Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Drugs for Oncology Revenue, (US$, Mn), 2019-2030
Figure 41. Roche Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Celgene Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Novartis Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Bristol-Myers Squibb Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Johnson & Johnson Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Merck & Co. Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. AstraZeneca Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Pfizer Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Amgen Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Eli Lilly Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. AbbVie Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Takeda Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Astellas Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. Ipsen Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Sanofi Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Bayer Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. Biogen Idec Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 58. Teva Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 59. Otsuka Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 60. Eisai Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 61. Merck KGaA Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 62. Gilead Sciences Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
